Good summary on the 4D of recent developments.FDA approval is...

Good summary on the 4D of recent developments.FDA approval is key and ignored by market - even though that's a major hurdles for most medtech and biotech players on the ASX (and elsewhere). That raises their profile to another patamar in the eyesof customers and OEMs.

Despite the lousy share price - similar to when the company had no products, no customers, no OEM paying then and was in litigation with Labcon. Amazing.

BCT has cone along way in the past 9 months and 2022 is looking very good (and the best it has ever did for the stock). On the right track so I'm happy how it looks now.